Jun 08, 2020
Protalix BioTherapeutics Appoints Yael Hayon, Ph.D. as its New Vice President, Research and Development
Jun 01, 2020
Protalix BioTherapeutics Reports First Quarter 2020 Financial Results and Business Update
May 28, 2020
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Submission of Biologics License Application to U.S. Food and Drug Administration for Pegunigalsidase Alfa for the Treatment of Fabry Disease
May 22, 2020
Protalix BioTherapeutics to Hold First Quarter 2020 Financial Results and Business Update Conference Call on June 1, 2020
May 11, 2020
Protalix BioTherapeutics Announces Positive Topline Results from the BRIDGE Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry Disease
Mar 18, 2020
Protalix BioTherapeutics Announces Closing of $43.7 Million Private Placement
Mar 16, 2020
Protalix Biotherapeutics Announces Feasibility Study with Kirin Holdings on the Production of a Novel Complex Protein
Mar 12, 2020
Protalix BioTherapeutics Announces $43.7 Million in Financing to Further Advance its Programs in Fabry Disease
Mar 05, 2020
Protalix BioTherapeutics to Hold Fourth Quarter and Full-Year 2019 Financial and Business Results Conference Call on March 12, 2020
Feb 10, 2020
Protalix BioTherapeutics Presents Key Clinical Data of Pegunigalsidase Alfa for the Treatment of Fabry Disease at the 16th Annual WORLDSymposium(TM) 2020
Feb 06, 2020
Protalix BioTherapeutics and Chiesi Farmaceutici Announce Receipt of "Agreement Letter" for Initial Pediatric Study Plan for PRX-102 for the Treatment of Fabry Disease
Feb 04, 2020
Protalix BioTherapeutics to Participate in the 2020 BIO CEO & Investor Conference and the Noble Capital Markets' 16th Annual Small & Microcap Investor Conference
Jan 30, 2020
Protalix BioTherapeutics to Participate in the 16th Annual WORLDSymposium(TM) 2020
Dec 19, 2019
Protalix BioTherapeutics Adds Two Accomplished Biopharmaceutical Executives to its Board of Directors
Dec 09, 2019
Protalix BioTherapeutics Announces 1-for-10 Reverse Stock Split
Nov 27, 2019
Protalix BioTherapeutics Hosting Key Opinion Leader Meeting on PRX-102 Drug Candidate for the Treatment of Fabry Disease
Nov 18, 2019
Protalix BioTherapeutics and Chiesi Farmaceutici Announce Successful pre-BLA Meeting with FDA for Accelerated Approval of pegunigalsidase alfa for the Treatment of Fabry Disease in the United States
Nov 07, 2019
Protalix BioTherapeutics Reports Third Quarter 2019 Results and Provides Corporate Update
Oct 29, 2019
Protalix BioTherapeutics to Release Third Quarter 2019 Financial Results and Business Update on November 7, 2019
Sep 24, 2019
Protalix BioTherapeutics and Chiesi Group Complete Enrollment in the Third Phase III Clinical Trial of pegunigalsidase alfa (PRX-102) for the Treatment of Fabry Disease